X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (30) 30
humans (29) 29
oncology (27) 27
female (25) 25
middle aged (21) 21
aged (20) 20
cancer (20) 20
adult (16) 16
ovarian cancer (14) 14
chemotherapy (11) 11
male (11) 11
neoplasms - drug therapy (10) 10
tumors (10) 10
patients (9) 9
aged, 80 and over (8) 8
breast cancer (8) 8
clinical trials (8) 8
ovarian neoplasms - drug therapy (8) 8
poly polymerase (8) 8
prognosis (8) 8
solid tumors (8) 8
care and treatment (7) 7
maximum tolerated dose (7) 7
neoplasm staging (7) 7
acetylation (6) 6
hematology, oncology and palliative medicine (6) 6
mutation (6) 6
ovarian neoplasms - pathology (6) 6
survival rate (6) 6
treatment outcome (6) 6
administration, oral (5) 5
analysis (5) 5
antineoplastic agents - therapeutic use (5) 5
brca1 protein - genetics (5) 5
brca2 protein - genetics (5) 5
carcinoma, ovarian epithelial (5) 5
fallopian-tube (5) 5
histones - metabolism (5) 5
medical research (5) 5
neoplasms, glandular and epithelial - drug therapy (5) 5
open-label (5) 5
ovarian carcinoma (5) 5
ovarian neoplasms - genetics (5) 5
pharmacokinetics (5) 5
pharmacology (5) 5
survival (5) 5
toxicity (5) 5
antineoplastic agents (4) 4
biomarkers (4) 4
brca1 protein (4) 4
carcinoma (4) 4
disease-free survival (4) 4
endometrial cancer (4) 4
histone deacetylase inhibitors (4) 4
inhibitor (4) 4
metastasis (4) 4
multicenter (4) 4
neoplasms - pathology (4) 4
obstetrics & gynecology (4) 4
platinum (4) 4
poly polymerase inhibitors - therapeutic use (4) 4
animals (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
article (3) 3
bevacizumab (3) 3
breast (3) 3
cancer patients (3) 3
cancer therapies (3) 3
carcinoma, endometrioid - pathology (3) 3
drug development (3) 3
drug discovery (3) 3
endometrial neoplasms - pathology (3) 3
enzyme inhibitors - pharmacology (3) 3
epithelial ovarian (3) 3
erbb-2 protein (3) 3
follow-up studies (3) 3
germ-line mutation (3) 3
hdac inhibitor (3) 3
medical treatment (3) 3
medicine, experimental (3) 3
metastases (3) 3
monosaccharides (3) 3
neoplasm metastasis (3) 3
neoplasms - metabolism (3) 3
neoplasms, glandular and epithelial - genetics (3) 3
olaparib (3) 3
ovarian-cancer (3) 3
patient selection (3) 3
peritoneal neoplasms - drug therapy (3) 3
pharmacology & pharmacy (3) 3
prognostic-factors (3) 3
randomization (3) 3
repair (3) 3
research (3) 3
retrospective studies (3) 3
suberoylanilide hydroxamic acid (3) 3
sugars (3) 3
therapy (3) 3
vomiting (3) 3
womens health (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4095 - 4106
Journal Article
Journal of Medical Genetics, ISSN 0022-2593, 03/2019, Volume 56, Issue 3, pp. 195 - 198
BackgroundOvarian cancer is the fifth most common cause of cancer death for women in the UK. Up to 18% of cases can be attributed to germline mutations in... 
BRCA | mainstreaming | ovarian cancer | genetic testing | GENETICS & HEREDITY | MUTATIONS | BRCA2 protein | BRCA1 protein | Womens health | Ribose | Poly(ADP-ribose) polymerase | Breast cancer | Mutation | Health risk assessment | Patients | Genetic screening | Ovarian cancer
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 05/2011, Volume 8, Issue 5, pp. 302 - 306
Journal Article
British Journal of Cancer, ISSN 0007-0920, 08/2018, Volume 119, Issue 4, pp. 487 - 491
Journal Article
British Journal of Cancer, ISSN 0007-0920, 02/2019, Volume 120, Issue 4, pp. 379 - 386
BACKGROUND: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulinliposomal formulation (eribulin-LF) in... 
MECHANISM | ONCOLOGY | MESYLATE E7389 | METASTATIC BREAST-CANCER | Schedules | Alanine | Toxicity | Transaminase | Radioactive half-life | Pharmacology | Patients | Stomatitis | Safety engineering | Alanine transaminase | Hypophosphatemia | Solid tumors | Pharmacokinetics | Tumors | Neutropenia | Index Medicus | Breast cancer
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2015, Volume 21, Issue 1, pp. 77 - 86
Journal Article
Journal Article